> Just because the FDA appears to be moving toward allowing Plan B to go OTC, don't expect Democrats to stop blocking Dr. Andrew von Eschenbach's nomination to run the agency. They want a firm decision on the contraceptive, saying they were misled in the past. Report
> UCB says that the FDA has approved Keppra intravenous for epilepsy. Report
> Northfield Laboratories had an uphill climb, but they finished enrolling for a late-stage trial of their controversial blood substitute PolyHeme. Report
> Japan's Daiichi Sankyo is suing Mylan over its plans to make a copycat version of its hypertensive drug Benicar. Report
> Cerexa says it received positive Phase II data on Ceftaroline for the treatment of complicated skin and skin structure infections. Release
> Pain Therapeutics and King Pharmaceuticals have commenced a Phase I trial of the pain therapy PTI-202. Report
> ISTA Pharmaceuticals has agreed to pay $6 million up front plus royalties for the North American rights to bepotastine from Senju Pharmaceutical. Report
And Finally… Researchers have been exploring testicular cancer at the molecular level to see why it responds so well to treatment when other metastatic cancers are resistant. Article